Company & Sponsor Intelligence

Taiho Oncology, Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting1

Completed1

Countries1

Therapeutic footprint

epilepsyout_of_scope

Indexed studies

NCT00400179A Safety and Efficacy Study in Patients With Gastric Cancer
out_of_scope · United StatesPHASE3

NCT05973773REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
out_of_scope · United StatesPHASE3

NCT02134067Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
epilepsy · United StatesPHASE1

Intelligence layer updated: 2026-10-12 03:39:50.393311+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →